Condition (MeSH)
Leukemia, Prolymphocytic, T-Cell
ClinicalTrials.gov lists 30 trials for Leukemia, Prolymphocytic, T-Cell or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
30 of the 30 trials are tagged with Leukemia, Prolymphocytic, T-Cell itself; the rest are tagged with a narrower condition beneath it.
When did Leukemia, Prolymphocytic, T-Cell trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 4 |
| 2020 | 3 |
| 2017 | 2 |
| 2016 | 1 |
| 2013 | 1 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 8 trials still running at the 2026-10-09 snapshot; registered median of 70 months across 17 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Leukemia, Prolymphocytic, T-Cell trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 14 |
| Phase 1/2 | 5 |
| Phase 2 | 8 |
| Phase 3 | 1 |
| Observational | 2 |
How many Leukemia, Prolymphocytic, T-Cell trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 9 |
| Active, not recruiting | 1 |
| Completed | 15 |
| Suspended | 1 |
| Terminated | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Leukemia, Prolymphocytic, T-Cell trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| AbbVie | 1 |
| Ascentage Pharma Group Inc. | 1 |
| Geron Corporation | 1 |
| Kymera Therapeutics, Inc. | 1 |
| National Cancer Institute (NCI) | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Leukemia, Prolymphocytic, T-Cell? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Duvelisib | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SQ Fludarabine | 7 |
| Total Body Irradiation | 5 |
| Mofetil Mycophenolate | 5 |
| Cyclosporine 0.05% | 4 |
| Peripheral blood stem cell transplantation | 4 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Leukemia, Prolymphocytic, T-Cell trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| DISEASE PROGRESSION | 4 | 1 |
| Acute kidney injury | 2 | 1 |
| Death following disease progression post transplant | 2 | 1 |
| MALIGNANT NEOPLASM PROGRESSION | 2 | 1 |
| Pulmonary failure requiring intubation | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Leukemia, Prolymphocytic, T-Cell? (6)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance. | Leukemia & lymphoma | 2019 | Yes |
| <sup>18</sup>F-Fludarabine PET for Lymphoma Imaging: First-in-Humans Study on DLBCL and CLL Patients. | Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2018 | Yes |
| Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. | Cancer | 2013 | Yes |
| Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2002 | Yes |
| Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues. | Leukemia & lymphoma | 1994 | Yes |
Showing 5 of 6 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| T-cell prolymphocytic leukemia | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| T-cell prolymphocytic leukemia | Annual incidence | Unknown | Worldwide | Not stated | Exact |
| T-cell prolymphocytic leukemia | Annual incidence | Unknown | Worldwide | Not stated | Unspecified |
| T-cell prolymphocytic leukemia | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| T-cell prolymphocytic leukemia | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| T-cell prolymphocytic leukemia | 86871 | Exact | Orphadata Science knowledge files, Product 1 |
| T-cell prolymphocytic leukemia | 86871 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.